Daniel Morgensztern, MD

Medical Oncologist

Daniel Morgensztern

Appointment Options

Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.

My Locations

Gary C. Werths Building at Siteman Cancer Center

Gary C. Werths Building at Siteman Cancer Center

On WashU Medicine Campus
4500 Forest Park Avenue, Saint Louis, MO 63108

Expertise & Training

Clinical Expertise

  • Lung cancer

Primary Academic Title

Professor of Medicine, Division of Oncology, Section of Medical Oncology, WashU Medicine

Board Certification

  • 2001: American Board of Internal Medicine, Internal Medicine
  • 2004: American Board of Internal Medicine, Medical Oncology

Training

  • 1996 - 1998: Resident, Internal Medicine and Hematology, State University of Rio de Janeiro, Brazil
  • 1998 - 2001: Resident, Internal Medicine, University of Miami-Jackon Memorial Hospital, Miami, FL
  • 2001 - 2004: Fellow, Hematology and Oncology, University of Miami-Jackson Memorial Hospital, Miami, FL

Education

  • 199: MD, Fundação Técnico-Educational Souza Marques, Rio de Janeiro, Brazil

Research & Select Publications

Research Interest

Main clinical and translational research interests are in the development of new Phase II clinical studies for patients with lung cancer

Research Publications

PROSPECT-LUNG: A National Clinical Trials Network Trial Advancing Pragmatic Innovation in Cancer Clinical Trials
Authors:

Booth A, Hillman S, Laumann K, one or more additional authors omitted Morgensztern D, Mandrekar SJ

Journal & Year:

J Thorac Oncol | 2026

Erratum: Real-World Adherence Patterns of Comprehensive Genomic Profiling to Biomarker Recommended Therapies in Patients With Advanced Non-Small Cell Lung Cancer
Authors:

Ben-Shachar R, Nadhamuni K, Raez LE, one or more additional authors omitted Morgensztern D

Journal & Year:

JCO Oncol Pract | 2026

Reply to: Delta-Like Ligand 3 Expression Across Lung Neuroendocrine Subtypes: Interpreting Response in Small Cell Lung Cancer and Beyond
Authors:

Wermke M, Gambardella V, Kuboki Y, one or more additional authors omitted Morgensztern D

Journal & Year:

J Clin Oncol | 2026

Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer
Authors:

Park W, Kasi A, Spira AI, one or more additional authors omitted Morgensztern D, one or more additional authors omitted Goldman JW

Journal & Year:

N Engl J Med | 2026

Non-Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology
Authors:

Riely GJ, Wood DE, Aisner DL, one or more additional authors omitted Morgensztern D, one or more additional authors omitted Hang L

Journal & Year:

J Natl Compr Canc Netw | 2026

Real-World Adherence Patterns of Comprehensive Genomic Profiling to Biomarker Recommended Therapies in Patients With Advanced Non-Small Cell Lung Cancer
Authors:

Ben-Shachar R, Nadhamuni K, Raez LE, one or more additional authors omitted Morgenstzern D

Journal & Year:

JCO Oncol Pract | 2026

Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
Authors:

Johnson ML, Smit EF, Felip E, one or more additional authors omitted Morgensztern D, one or more additional authors omitted Riely GJ

Journal & Year:

J Clin Oncol | 2025

Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report
Authors:

Riely GJ, Ahn MJ, Clarke JM, one or more additional authors omitted Morgensztern D, one or more additional authors omitted Johnson BE

Journal & Year:

J Thorac Oncol | 2025

Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuro…
Authors:

Wermke M, Gambardella V, Kuboki Y, one or more additional authors omitted Morgensztern D

Journal & Year:

J Clin Oncol | 2025

NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 7.2025
Authors:

Riely GJ, Wood DE, Aisner DL, one or more additional authors omitted Morgensztern D, one or more additional authors omitted Hang L

Journal & Year:

J Natl Compr Canc Netw | 2025

JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
Authors:

Kang D, Wang Y, Lin Y, one or more additional authors omitted Morgensztern D, one or more additional authors omitted Wang Y

Journal & Year:

Clin Cancer Res | 2025

Thymomas and Thymic Carcinomas, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Authors:

Riely GJ, Wood DE, Loo BW, one or more additional authors omitted Morgensztern D, one or more additional authors omitted Hang L

Journal & Year:

J Natl Compr Canc Netw | 2025

Toripalimab for Extensive-Stage Small Cell Lung Cancer
Authors:

Cali Daylan AE, Morgensztern D, Waqar SN

Journal & Year:

JAMA Oncol | 2025

A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer
Authors:

Morgensztern D, Ready N, Johnson ML, one or more additional authors omitted Furqan M

Journal & Year:

Clin Cancer Res | 2024

Actionable Structural Variant Detection via RNA-NGS and DNA-NGS in Patients With Advanced Non-Small Cell Lung Cancer
Authors:

Owen D, Ben-Shachar R, Feliciano J, one or more additional authors omitted Morgensztern D

Journal & Year:

JAMA Netw Open | 2024